Though ischemic outcomes numerically favored the Amulet, confirmation in future studies is needed, experts say.

Lipoprotein(a), or Lp(a), was successfully reduced in phase II trials of muvalaplin and zerlasiran. (JAMA) The possibility of a drug interaction between SGLT2 inhibitors and statins was not ...